Travere Therapeutics Inc. has announced that on May 10, 2025, its Compensation Committee granted inducement equity grants to six new employees. These grants consist of restricted stock units (RSUs) covering a total of 35,900 shares of Travere's common stock. The RSUs are issued under the terms of Travere's 2018 Equity Incentive Plan, although they were granted outside of this plan as inducements for the new employees joining the company, in compliance with Nasdaq Listing Rule 5635(c)(4). The RSUs will vest over four years, with 25% vesting on each anniversary of the grant date, contingent upon the employees' continued service with Travere.
免責聲明：投資有風險，本文並非投資建議，以上內容不應被視為任何金融產品的購買或出售要約、建議或邀請，作者或其他用戶的任何相關討論、評論或帖子也不應被視為此類內容。本文僅供一般參考，不考慮您的個人投資目標、財務狀況或需求。TTM對信息的準確性和完整性不承擔任何責任或保證，投資者應自行研究並在投資前尋求專業建議。